BMO Capital Cuts PT on BioNTech SE (BNTX) to $128 From $143 – Here’s Why

BioNTech SE (NASDAQ:BNTX) is one of the best high growth healthcare stocks to buy now. On March 11, BMO Capital cut the price target on BioNTech SE (NASDAQ:BNTX) to $128 from $143 and reiterated an Outperform rating on the shares. The firm told investors in a research note that the company’s underwhelming 2026 COVID guide and confusing CEO departure messaging inject uncertainty ahead of BioNTech’s “major year for data”. It added that factors such as the uncertainty regarding the new leadership in light of a vast mid-to-late-stage pipeline and accelerating COVID revenue erosion give the firm pause on the stock.

Why BioNTech SE (BNTX) Skyrocketed On Monday

BioNTech SE (NASDAQ:BNTX) also received a rating update from Morgan Stanley on March 11. The firm cut the price target on the stock to $125 from $134 and maintained an Overweight rating on the shares, telling investors that the company surprisingly announced a leadership transition in conjunction with its Q4 report. This overshadowed the fiscal Q4 results and the initial 2026 guidance. However, the firm added that it sees shares as undervalued ahead of a number of data read-outs following the selloff in the stock.

BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that creates messenger RNA (mRNA) therapeutics and vaccines to address serious diseases such as cancer and infectious diseases. It specializes in developing and manufacturing immunotherapies for patient-specific approaches.

While we acknowledge the risk and potential of BNTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BNTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.